Got Loblaw shares in your investment portfolio? Why Canadians shouldn't count on the Westons' CA$11.2B Boots deal — what investors need to know

Boots operates roughly 1,800 U.K. stores — and the possibility of owning a share of the successful U.K. drugstore chain excites many would-be investors. But don’t get too excited: a Weston deal isn’t automatically a Loblaw deal.

Here’s why investors in Loblaw Companies shares probably won’t own a piece of Boots — and what to check before you buy or sell shares of the great Canadian grocery store.

Who would actually own Boots?

The family would make the purchase through Wittington Investments, a private investment company, according to Private Equity Wire, a trade publication covering private capital.

That detail matters. Wittington isn’t listed on any stock exchange, so you can’t buy its shares. It sits at the top of the family’s Canadian holdings. Wittington, controlled by Galen G. Weston, held approximately 59.2% of George Weston Limited (GWL) as of August 2025, according to a company announcement. GWL (TSX:WN), in turn, held 613.8 million Loblaw shares as of Mar. 28, 2026, a controlling stake, according to its first-quarter report.

What does this mean? It means the acquisition of Boots puts the asset alongside Loblaws, not inside the publicly traded firm. While owning Loblaw stock would still give investors a slice of Weston business — not a slice of the family’s overall asset mix. (Yes, pun intended.)

Could Loblaw shareholders benefit anyway?

For investors looking to cash-in on the U.K. pharmacy deal, the idea of owning Loblaw Companies (TSX: L) stock may be appealing based on proximity value; the possibility that Loblaw Companies shares could grow in value due to this recent acquisition. But that’s not likely.

Since no publicly traded company has been named in the talks and if Wittington buys Boots, then the U.K. pharmacy’s sales and profits would flow to the Weston family’s private company, not into Loblaw’s or GWL’s financial results.

But what about the connection? The fact that U.K.-based Boots and Canada-based Shopper’s Drug Mart both sell prescriptions, beauty products and health services means there could be a partnership — and this could have knock-on effects for investors. But any partnership between the two would be speculation until a public company discloses it.

It’s also worth remembering the deal isn’t done. Boots and Sycamore declined to comment, and Wittington didn’t immediately respond to requests, Private Equity Wire reports. And keep in mind, stalled talks already occurred when the two sides hit an impasse in August after the family lowered its offer, according to trade publication The Industry Beauty.

What actually moves your Loblaw shares?

For investors, the only move that matters is Loblaw’s own results.